There is sparse information on the safety of early primary discharge from the emergency department (ED) after rule-out of myocardial infarction in suspected acute coronary syndrome (ACS).
https://bmjopen.bmj.com/content/9/7/e028311.full
Differential diagnosis of diabetes insipidus is challenging. The most reliable approach is hypertonic saline-stimulated copeptin measurements.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31255-3/fulltext >
Diabetes insipidus (DI), be it from central or nephrogenic origin, must be differentiated from secondary forms of hypotonic polyuria such as primary polydipsia. Differentiation is crucial since wrong treatment can have deleterious consequences.
https://eje.bioscientifica.com/view/journals/eje/181/1/EJE-19-0163.xml >
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
https://www.kidney-international.org/article/S0085-2538(19)30041-9/abstract >
The combined copeptin/cTN testing has the potential to save costs and staff time in acute
care and for the entire hospital stay. The primary explanations for these findings are early
identification and ruling out patients without AMI along with the associated reduced need for
acute medical treatment.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202133 >